Juvenescence acquires AI drug discovery company Ro5

AI-enabled biotech Juvenescence today announced the acquisition of Ro5 Inc, a proprietary AI drug discovery company.

This acquisition, financial terms of which were not disclosed, enhances Juvenescence’s artificial intelligence/machine learning drug discovery capabilities and forms a central component of its strategic partnership with Abu Dhabi-based global healthcare company M42, announced in April 2025.

Ro5’s platform leverages a proprietary Biomedical Knowledge Graph, comprising over 85 million nodes and approximately 400 million relationships, to uncover novel associations in biological processes and enable a robust evaluation of drug targets based on biological, therapeutic, and market potential. The company’s AI Chemistry Platform incorporates state-of-the art machine learning model and cheminformatics tools, facilitating rapid and efficient discovery and design of novel compounds from hit identification through to lead optimisation.